Kester Capital banks on multibillion-dollar drug discovery software market with Optibruim buyout
Drug discovery software provider Optibrium has been bought by Kester Capital in the firm's third deal since closing its £90m sophomore fund.
Drug discovery software provider Optibrium has been bought by Kester Capital in the firm's third deal since closing its £90m sophomore fund.
Recent Comments